-
公开(公告)号：US09539262B2
公开(公告)日：2017-01-10
申请号：US14691167
申请日：2015-04-20
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.
Inventor： Ajay Jaysingh Khopade , Arindam Halder , Subhas Balaram Bhowmick
IPC: A61K31/5575 , A61K47/14 , A61K9/00 , A61K9/107 , A61K31/00
CPC classification number: A61K31/5575 , A61K9/0048 , A61K9/1075 , A61K31/00 , A61K47/14
Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Abstract translation: 本发明涉及适用于眼用的药物组合物，其包含一种或多种前列腺素衍生物或盐，稳定量的聚乙二醇羟基硬脂酸酯和药学上可接受的载体。
-
公开(公告)号：US20140030352A1
公开(公告)日：2014-01-30
申请号：US14045250
申请日：2013-10-03
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Ajay Jaysingh KHOPADE , Subhas Balaram BHOWMICK , Natarajan ARULSUDAR
IPC: A61K9/10 , A61K9/08 , A61K9/14 , A61K31/337
CPC classification number: A61K9/10 , A61K9/08 , A61K9/1075 , A61K9/146 , A61K9/5138 , A61K9/5146 , A61K31/337
Abstract: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.
Abstract translation: 本发明提供纳米分散体，其包含分散在包含水混溶性溶剂和水的载体中的平均粒径小于300nm的纳米颗粒，所述纳米颗粒包含一种或多种紫杉烷衍生物，聚合物和包含脂肪酸或其混合物的混合物的表面活性剂 盐和甾醇或其衍生物或其盐。
-
公开(公告)号：US11951106B2
公开(公告)日：2024-04-09
申请号：US17304309
申请日：2021-06-17
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Ajay Jaysingh Khopade , Arindam Halder
CPC classification number: A61K31/498 , A61K9/0048 , A61K9/0051 , A61K9/08 , A61K9/1635 , A61K9/5176 , A61K45/06 , B01J39/20 , A61K31/498 , A61K2300/00
Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
-
公开(公告)号：US11931359B2
公开(公告)日：2024-03-19
申请号：US18061848
申请日：2022-12-05
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Ajay Jaysingh Khopade , Arindam Halder
CPC classification number: A61K31/498 , A61K9/0048 , A61K9/0051 , A61K9/08 , A61K9/1635 , A61K9/5176 , A61K45/06 , B01J39/20 , A61K31/498 , A61K2300/00
Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
-
公开(公告)号：US20240066014A1
公开(公告)日：2024-02-29
申请号：US18378901
申请日：2023-10-11
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin Krishnaji DAMLE , Sanjay Nandlalji MANDHANE , Manoj Atmaramji UPADHYA , Sameer Vishwanath MEHETRE , Gajanan Uttamrao CHIDREWAR , Prabal SENGUPTA , Trinadha Rao CHITTURI
Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I
wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen;
or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.-
Patent Agency Ranking
公开(公告)号：US09980917B2
公开(公告)日：2018-05-29
申请号：US15441712
申请日：2017-02-24
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/48 , A61K31/137 , A61K9/20 , A61K31/135 , A61K31/5517
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
-
公开(公告)号：US20170189339A1
公开(公告)日：2017-07-06
申请号：US15467713
申请日：2017-03-23
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/20 , A61K31/167 , A61K31/433 , A61K31/137
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
-
公开(公告)号：US20170157060A1
公开(公告)日：2017-06-08
申请号：US15441712
申请日：2017-02-24
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/48 , A61K31/5517 , A61K31/135 , A61K31/137 , A61K9/20
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
-
公开(公告)号：US20170056401A1
公开(公告)日：2017-03-02
申请号：US15042479
申请日：2016-02-12
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Nitin Bhalachandra DHARMADIKARI , Yashoraj ZALA , Ashwini GADKARI
IPC: A61K31/505 , A61K9/48
CPC classification number: A61K31/505 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/4858 , A61K9/4866 , A61K9/5031 , A61K9/5042 , A61K9/5047
Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.
Abstract translation: 一种稳定的多颗粒药物组合物，其包含丸粒，所述丸粒包含作为唯一活性成分的瑞舒伐他汀或其药学上可接受的盐的混合物，一种或多种渗透释放改性剂和一种或多种稳定剂。
-
40.发明申请公开(公告)号：US20150272902A1
公开(公告)日：2015-10-01
申请号：US14667826
申请日：2015-03-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
IPC: A61K9/70
CPC classification number: A61K9/2081 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2846 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/5026 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/433 , A61K31/5517 , A61K2300/00
Abstract: An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
Abstract translation: 滥用威慑立即释放双相基质固体剂型，当口服单一单位或剂型的规定单位时，以期望的速率释放药物以快速起效，但当超过规定数量时显示降低的释放速率 的单位，被管理。
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.045 seconds)
